Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

NOVAVAX INC

CIK 1000694 NVAX·Biological Products · All EDGAR filings ↗

Going concern Filing comparison

NOVAVAX INC no longer discloses a going-concern conclusion

Substantial doubt raised, alleviated by management's plans No going-concern disclosure

During the year ended December 31, 2025, the Company recognized net income of $440.3 million and had net cash flows used in operating activities of $244.6 million. In accordance with Accounting Standards Codification (“ASC”) Topic 205-40, Presentation of Financial Statements - Going Concern, the Company evaluated its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Based on the Company’s current cash, cash equivalents, and marketable securities balances and the Company's current cash flow forecast for the one-year…
Evidence
Blank check
No
Comparable
Yes
Current state
none
Current state label
No going-concern disclosure
Direction
eased
Located in
going-concern note
Prior filed
2025-02-27
Prior form
10-K
Prior state
doubt_alleviated
Prior state label
Substantial doubt raised, alleviated by management's plans
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.